Results 21 to 30 of about 6,178 (191)

Safety and Efficacy of Iron Chelators in Patients With Chronic Kidney Disease: A Systematic Review and Meta-Analysis. [PDF]

Hemodial Int
ABSTRACT Background Iron overload in chronic kidney disease contributes to oxidative injury. The role of iron chelators, standard in transfusion‐related overload, remains unclear in chronic kidney disease. Aim To evaluate the efficacy and safety of iron chelators in adults with chronic kidney disease.
Rajha HE, Shamoon R, Almeshagbeh A, Masry S, Alqatati F, Abuajameia BH, Nashwan AJ.   +6 more
europepmc   +2 more sources

Iron and Other Metal Ions in Human Health and Disease. [PDF]

MedComm (2020)
Iron, copper, zinc, and calcium orchestrate cellular function through distinct yet cooperative mechanisms: redox‐active iron and copper cycle between oxidation states to act as Fenton catalysts and electron carriers in oxidative phosphorylation (OXPHOS); redox‐inert zinc serves as a structural component of zinc‐finger proteins and a catalytic cofactor ...
Dai X, Li J.
europepmc   +2 more sources

Antioxidant Activity of Deferasirox and Its Metal Complexes in Model Systems of Oxidative Damage: Comparison with Deferiprone

Molecules, 2021
Deferasirox is an orally active, lipophilic iron chelating drug used on thousands of patients worldwide for the treatment of transfusional iron overload. The essential transition metals iron and copper are the primary catalysts of reactive oxygen species
Viktor A. Timoshnikov, Lilia A. Kichigina, Olga Yu. Selyutina, Nikolay E. Polyakov, George J. Kontoghiorghes   +4 more
doaj   +1 more source

Aceruloplasminemia Presenting With Prominent Psychiatric Symptoms and Neurodegeneration: A Case Report. [PDF]

Clin Case Rep
ABSTRACT Aceruloplasminemia (ACP) often presents with systemic, psychiatric, and neurological features. In this case, diabetes mellitus was diagnosed several years before psychiatric symptoms, which were then followed by neurological decline, which significantly delayed diagnosis.
Almarzooqi A, Almarzooqi A, Juma K, Kamalboor H.   +3 more
europepmc   +2 more sources

Management of Iron Overload in Infants and Toddlers With Diamond-Blackfan Anemia Syndrome: A French-Italian Study. [PDF]

Am J Hematol
ABSTRACT Diamond–Blackfan Anemia Syndrome (DBAS) is a rare congenital anemia often requiring chronic red blood cell transfusions from infancy. Without appropriate chelation, iron overload develops early and may be severe; however, no data are available on chelation in patients under 3 years of age.
Torchio F, Lecalvez B, Garelli E, Mallebranche C, Carando A, Castex MP, Garnier N, Zecca M, Aladjidi N, Bertoni E, Sterin A, Licciardello M, Sirvent A, Sau A, Marie I, Bruno B, Da Costa LM, Fagioli F, Quarello P, Leblanc T.   +19 more
europepmc   +2 more sources

Efficacy and Side Effects of Deferasirox and Deferiprone for Thalasemia Major in Children [PDF]

Pharmacology and Clinical Pharmacy Research, 2016
Thalassemia major (TM) is an inherited disease caused by defective or absent of hemoglobin chain synthesis. Regular chelation therapy is necessary to reduce excess iron in several organs of TM patients.
Asti Y. Rindarwati, Ajeng Diantini, keri Lestari   +2 more
doaj   +1 more source

Development and Validation of a Method for Determining Deferasirox in Human Blood Plasma by HPLC-UV

Разработка и регистрация лекарственных средств, 2022
Introduction. Deferasirox is one of the most well-known complexing drugs chelators and is successfully used in chelating therapy for the treatment of excess iron in the human body. Deferasirox is also included in the list of vital and essential medicines,
P. A. Karpova, T. N. Komarov, O. A. Archakova, D. S. Shchelgacheva, A. V. Suvorova, N. S. Bagaeva, P. K. Karnakova, I. E. Shohin   +7 more
doaj   +1 more source

Hypersensitivity myocarditis following deferasirox administration [PDF]

, 2022
We describe a case of A 73-year-old woman, receiving regular blood transfusion for 2 years as affected by myelodysplasia and under treatment with deferasirox (14 mg/kg daily; 2 tablets of 360 mg/die) in the last 2 months due to the registration of high ...
Menafra, Vito, Verardo, Romina, Labbadia, Giancarlo, Antonio Russo, Matteo, Frustaci, Andrea, Galea, Nicola   +5 more
core   +1 more source

Evaluation of Hepatic Enzymes in major β-thalassemic Patients using Deferasirox

Iraqi Journal of Pharmaceutical Sciences, 2022
β-thalassemia major is a genetic disease that causes sever defect in normal hemoglobin synthesis. The patients with β-thalassemia major need periodic blood transfusions that can result in accumulation of body iron, so treatment with iron chelating agent ...
Ahmed Yahya Dallal Bashi, Fatimah Haitham Fathi   +1 more
doaj   +1 more source

Compliance and clinical benefit of deferasirox granule and dispersible tablet formulation in pediatric patients with transfusional iron overload: in a randomized, open-label, multicenter, phase II study

Haematologica, 2023
CALYPSO (clinicaltrials gov. Identifier: NCT02435212), a randomized, open-label, multicenter, phase II study evaluated the compliance, clinical benefits, and safety of deferasirox granules and dispersible tablets (DT) in pediatric patients with iron ...
Ali T. Taher, Yasser Wali, Maria Cecilia Cruz, Pimlak Charoenkwan, Yesim Aydinok, Olena Werner, Sameera Govindaraju, Fabian Romen, Vip Viprakasit   +8 more
doaj   +1 more source